Ensysce Biosciences, Inc. (NASDAQ:ENSC) has announced a strategic partnership and a key supply agreement to bolster the development and commercialization of its abuse-resistant pain relief products. These initiatives aim to provide safer options for patients suffering from severe pain while minimizing the risk of opioid abuse and overdose.
Strategic Partnership for PF614 and PF614-MPAR
Ensysce has entered into a strategic partnership with a leading specialty drug manufacturer to advance the development and commercial launch of its PF614 and PF614-MPAR drug products. This collaboration is designed to expedite regulatory approval and streamline the development process. The partner will provide Ensysce with clinical trial material, drug products for regulatory submissions, and initial commercial batches.
The partnership encompasses the complete manufacturing process, including packaging, labeling, and shipment of the products. As part of the agreement, the specialty drug manufacturer will take an equity position in Ensysce, facilitating resource allocation to clinical trials and commercialization activities. This also secures key Chemistry Manufacturing and Control (CMC) elements for the New Drug Application (NDA) submission.
"This partnership strengthens our ability to deliver quality drug products for clinical and commercial purposes starting with PF614 and PF614-MPAR," said Dr. Lynn Kirkpatrick, CEO of Ensysce Biosciences. "It ensures that all aspects of manufacturing, packaging, and distribution are handled efficiently, enabling us to focus on helping patients suffering from severe pain with innovative and safer solutions."
Securing Nafamostat Supply for Overdose Protection
Ensysce has also announced a commitment for the future supply of GMP nafamostat from Aurore Life Sciences, a manufacturer of Active Pharmaceutical Ingredients (APIs). Nafamostat is a critical component of Ensysce's PF614-MPAR, a drug product designed to provide breakthrough overdose protection.
This agreement secures the supply chain for PF614-MPAR and allows Ensysce to reference Aurore Life Sciences' nafamostat Drug Master File. "We are pleased to have received this early interest and commitment from Aurore as nafamostat is a vital component of our overdose protection program PF614-MPAR," commented Dr. Lynn Kirkpatrick. "Having a secure supply of this drug substance will accelerate our finalizing the drug product for PF614-MPAR, which is rapidly moving through clinical development."
Ensysce has also initiated additional programs with nafamostat as a single agent for other indications, which will benefit from this supply agreement.
About Ensysce's Technology
Ensysce Biosciences is focused on developing safer prescription drugs using its proprietary Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms. These platforms are designed to create tamper-proof treatment options for pain, minimizing the risk of drug abuse and overdose. The company's products aim to provide safer alternatives for patients with severe pain and help prevent deaths caused by medication abuse. Ensysce's technology is protected by a global intellectual property portfolio covering a wide range of prescription drug compositions.
